Sodium-glucose cotransporter-2 (SGLT2) inhibitors were originally developed to address type 2 diabetes mellitus (T2DM) by inhibiting glucose reabsorption in the renal proximal tubules. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.